欣力康胶囊抗结肠癌及增强机体免疫功能的作用研究  

Effect of Xinlikang capsules on anti-colon cancer and enhancing immune function

作　　者：皇苏州 张旭哲 吕高虹[1] 吴丽[1] 陈志鹏[1] 张丽娜 赵倩 刘馨[3] HUANG Su-zhou;ZHANG Xu-zhe;LYU Gao-hong;WU Li;CHEN Zhi-peng;ZHANG Li-na;ZHAO Qian;LIU Xin(School of Pharmacy,Nanjing University of Chinese Medicine,Nanjing210023;Shanghai Haitian Medical Technology,Shanghai 200000;Department of Pharmacy,Suzhou Municipal Hospital,Suzhou Jiangsu 215002)

机构地区：[1]南京中医药大学药学院,南京210023 [2]上海海天医药科技开发有限公司,上海200000 [3]苏州市立医院药学部,江苏苏州215002

出　　处：《中南药学》2025年第2期312-318,共7页Central South Pharmacy

基　　金：国家自然科学基金(No.81873287);江苏省中医药科技发展计划重点项目(No.ZD202306);南京中医药大学校级课题(No.012009230092)。

摘　　要：目的探讨欣力康胶囊抗结肠癌及增强机体免疫功能的作用。方法CCK-8法检测欣力康胶囊含药血清对结肠癌MC-38细胞活力的影响。采用皮下接种MC-38细胞的方法建立结肠癌皮下荷瘤小鼠模型,治疗组在造模后给予不同剂量欣力康胶囊(0.675、1.35、2.7 g·kg^(-1))或阳性对照药物PD-1抑制剂(10 mg·kg^(-1))进行干预,连续17 d。动态观察不同组别荷瘤小鼠皮下瘤体积变化情况;HE染色法观察肿瘤的组织病变情况;ELISA法测定各组小鼠血清中干扰素(IFN)-γ、白细胞介素(IL)-10、转化生长因子(TGF-β)水平;流式细胞术检测外周血中CD4^(+)T、CD8^(+)T和Treg细胞的比例。结果在体外细胞实验中,与空白对照组比较,20%欣力康胶囊含药血清能显著抑制MC-38细胞活力(P<0.05)。在整体动物实验中,与模型组比较,欣力康低、中、高剂量组均能显著降低肿瘤体积(P<0.05);病理检测结果显示,欣力康能增加肿瘤组织中的细胞坏死面积,减少细胞核分裂,其中以欣力康中剂量组效果最好;此外,欣力康中、高剂量组能显著降低小鼠血清中TGF-β水平(P<0.05)、升高IFN-γ水平(P<0.01);中剂量组还能降低IL-10水平(P<0.01);流式细胞术结果显示,欣力康中、高剂量组能降低小鼠外周血CD8^(+)T、Treg细胞水平,升高CD4^(+)T细胞水平(P<0.05)。结论欣力康胶囊能够发挥抗结肠癌作用以及调节免疫细胞比例,增强机体免疫功能。Objective To determine the anti-colon cancer mechanism of Xinlikang capsules in regulating the immune function.Methods CCK-8 assay was used to detect the effect of XLK capsule-containing serum on MC-38 cell viability.Subcutaneous inoculation of MC-38 cells was used to establish a tumor-bearing mouse model of colon cancer.The treatment group was given different doses of Xinlikang capsule(0.675,1.35 and 2.7 g·kg^(-1))or positive control drug PD-1 inhibitor(10 mg·kg^(-1))after the modelling,the drugs being administered for 17 consecutive days.We dynamically observed the subcutaneous tumor volume changes in different groups of mice.HE staining was used to observe the histopathology of tumors;while ELISA to determine the serum levels of interferon-γ(IFN-γ),interleukin-10(IL-10)and transforming growth factor-β(TGF-β),in each group.Flow CytoMetry detected the ratio of CD4^(+)T,CD8^(+)T and Treg cells in the peripheral blood.Results In the in vitro cellular assay,the viability of MC-38 cells was significantly inhibited by 20%Xinlikang-containing serum compared with that of the blank control group(P<0.01).In the whole-animal assay,compared with the model group,Xinlikang low-dose,medium-dose,and high-dose groups greatly reduced the volume of tumors(P<0.05).Pathology showed that Xinlikang increased the necrotic area of cells in the tumor tissues and reduced the division of cell nuclei,among which the Xinlikang middle-dose group had the best effect.In addition,the middle-dose and high-dose groups of Xinlikang significantly reduced the serum level of TGF-βin the mice(P<0.05),and elevated the level of IFN-γ(P<0.01);the middle-dose group also reduced the level of IL-10(P<0.01).The Flow CytoMetry showed that the middle-dose and high-dose groups of Xinlikang both reduced the levels of peripheral blood CD8^(+)T and Treg cells and increased the level of CD4^(+)T cells in the mice(P<0.05).Conclusion Xinlikang capsules play an anti-colon cancer role and enhance the body’s immune function by regulating the proportion of immu

关 键 词：MC-38 欣力康胶囊 CD4^(+)/CD8^(+) TREG细胞 细胞因子 

分 类 号：R967[医药卫生—药理学] R286[医药卫生—药学]